{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:14Z","timestamp":1790720354183,"version":"4.1.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n                  <jats:p>Peptide receptor radionuclide therapy (PRRT) has become an established treatment for patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) that express somatostatin receptors. Among the available agents, lutetium-177 DOTATATE is the most commonly used radiolabeled somatostatin analog and has demonstrated significant clinical benefits, including improved response rates and prolonged progression-free survival, as shown in landmark trials such as NETTER-1 and NETTER-2. As the incidence of GEP-NENs continues to rise, the use of PRRT in clinical practice has grown accordingly. However, this therapy is associated with a range of toxicities that can affect multiple organ systems over different timeframes, including acute, subacute, and long-term periods. This review provides a comprehensive overview of the adverse effects associated with PRRT and presents evidence-based strategies for their monitoring, prevention, and management. This review also discusses the evolving paradigm of screening for clonal hematopoiesis before PRRT treatment, as well as the use of steroids as prophylaxis to prevent carcinoid crisis and bowel obstruction. A multidisciplinary approach is essential to ensure the safe delivery of treatment, early detection of complications, and tailored patient care. As clinical experience with PRRT expands, continued refinement of supportive care strategies will be critical to optimizing outcomes and minimizing toxicity in this complex patient population.<\/jats:p>","DOI":"10.1007\/s11864-026-01379-z","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:18:05Z","timestamp":1768558685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients"],"prefix":"10.1007","volume":"27","author":[{"given":"Chirayu","family":"Mohindroo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"1379_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15798","volume":"8","author":"A Dasari","year":"2025","unstructured":"Dasari A, et al. Epidemiology of neuroendocrine neoplasms in the US. JAMA Netw Open. 2025;8:e2515798-e2515798. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15798.","journal-title":"JAMA Netw Open"},{"key":"1379_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"1379_CR3","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, et al. [177Lu] Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317.","journal-title":"Lancet"},{"key":"1379_CR4","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, et al. 177Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363.","journal-title":"Lancet Oncol"},{"key":"1379_CR5","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1007\/s00259-025-07246-7","volume":"52","author":"MN Gaze","year":"2025","unstructured":"Gaze MN, et al. Safety and dosimetry of [(177)Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: primary analysis of the phase II NETTER-P study. Eur J Nucl Med Mol Imaging. 2025;52:4001\u201315. https:\/\/doi.org\/10.1007\/s00259-025-07246-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR6","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324.","journal-title":"Clin Cancer Res"},{"key":"1379_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2967\/jnumed.118.215376","volume":"60","author":"M Gabriel","year":"2019","unstructured":"Gabriel M, Nilica B, Kaiser B, Virgolini IJ. Twelve-year follow-up after peptide receptor radionuclide therapy. J Nucl Med. 2019;60:524\u20139.","journal-title":"J Nucl Med"},{"key":"1379_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","volume":"46","author":"WA van der Zwan","year":"2019","unstructured":"van der Zwan WA, et al. Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46:704\u201317. https:\/\/doi.org\/10.1007\/s00259-018-4158-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589\u2013608. https:\/\/doi.org\/10.1038\/s41573-020-0073-9.","journal-title":"Nat Rev Drug Discov"},{"key":"1379_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jhbp.1014","volume":"28","author":"N Kobayashi","year":"2021","unstructured":"Kobayashi N, et al. Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2021;28:727\u201339. https:\/\/doi.org\/10.1002\/jhbp.1014.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1379_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, et al. NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with (177)Lu-DOTATATE. J Nucl Med. 2019;60:937\u201343. https:\/\/doi.org\/10.2967\/jnumed.118.230607.","journal-title":"J Nucl Med"},{"key":"1379_CR12","first-page":"1533","volume":"19","author":"JA Roscoe","year":"2011","unstructured":"Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19:1533\u20138.","journal-title":"Support Care Cancer"},{"key":"1379_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-024-00216-6","volume":"8","author":"SJ Sozio","year":"2024","unstructured":"Sozio SJ, Raynor W, Becker MC, Yudd A, Kempf JS. Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment. EJNMMI Rep. 2024;8:29. https:\/\/doi.org\/10.1186\/s41824-024-00216-6.","journal-title":"EJNMMI Rep"},{"key":"1379_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","volume":"35","author":"B de Keizer","year":"2008","unstructured":"de Keizer B, et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3] octreotate. Eur J Nucl Med Mol Imaging. 2008;35:749\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2214\/AJR.19.21123","volume":"213","author":"AT Kendi","year":"2019","unstructured":"Kendi AT, Halfdanarson TR, Packard A, Dundar A, Subramaniam RM. Therapy with 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors. AJR Am J Roentgenol. 2019;213:309\u201317.","journal-title":"AJR Am J Roentgenol"},{"key":"1379_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.03.002","volume":"66","author":"GT Rico","year":"2018","unstructured":"Rico GT, Li M, Pavlakis N, Cehic G, Price TJ. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions. Cancer Treat Rev. 2018;66:1\u20136.","journal-title":"Cancer Treat Rev"},{"key":"1379_CR17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7186","author":"AK Gade","year":"2020","unstructured":"Gade AK, Olariu E, Douthit NT. Carcinoid syndrome: a review. Cureus. 2020. https:\/\/doi.org\/10.7759\/cureus.7186.","journal-title":"Cureus"},{"key":"1379_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jcrc.2020.08.011","volume":"60","author":"J Dhanani","year":"2020","unstructured":"Dhanani J, et al. Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. J Crit Care. 2020;60:319\u201322. https:\/\/doi.org\/10.1016\/j.jcrc.2020.08.011. https:\/\/doi.org:.","journal-title":"J Crit Care"},{"key":"1379_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072203","author":"MI Del Olmo-Garc\u00eda","year":"2020","unstructured":"Del Olmo-Garc\u00eda MI, et al. Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9072203.","journal-title":"J Clin Med"},{"key":"1379_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.surg.2018.04.093","volume":"165","author":"ME Condron","year":"2019","unstructured":"Condron ME, et al. A prospective study of the pathophysiology of carcinoid crisis. Surgery. 2019;165:158\u201365. https:\/\/doi.org\/10.1016\/j.surg.2018.04.093.","journal-title":"Surgery"},{"key":"1379_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jcrc.2020.08.015","volume":"60","author":"RF Pommier","year":"2020","unstructured":"Pommier RF. Invited commentary on octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by a novel peptide receptor radionuclie therapy (PRRT): A case report. J Crit Care. 2020;60:323\u20135. https:\/\/doi.org\/10.1016\/j.jcrc.2020.08.015.","journal-title":"J Crit Care"},{"key":"1379_CR22","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1245\/s10434-023-14876-4","volume":"31","author":"BH McCully","year":"2024","unstructured":"McCully BH, Kozuma K, Pommier S, Pommier RF. Comparison of octreotide and vasopressors as First-Line treatment for intraoperative carcinoid crisis. Ann Surg Oncol. 2024;31:2996\u20133002. https:\/\/doi.org\/10.1245\/s10434-023-14876-4.","journal-title":"Ann Surg Oncol"},{"key":"1379_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500\u201316. https:\/\/doi.org\/10.1148\/rg.352140164.","journal-title":"Radiographics"},{"key":"1379_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.18.19953","volume":"211","author":"ES Mittra","year":"2018","unstructured":"Mittra ES. Neuroendocrine tumor therapy: 177Lu-DOTATATE. Am J Roentgenol. 2018;211:278\u201385.","journal-title":"Am J Roentgenol"},{"key":"1379_CR25","volume":"2017","author":"J Stenzel","year":"2017","unstructured":"Stenzel J, Noe S, Holzapfel K, Erlmeier F, Eyer F. Fatal systemic vasoconstriction in a case of metastatic small-intestinal NET. Case Rep Gastroenterol Med. 2017;2017:9810194.","journal-title":"Case Rep Gastroenterol Med"},{"key":"1379_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105:295\u2013309.","journal-title":"Neuroendocrinology"},{"key":"1379_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","volume":"42","author":"M Hamiditabar","year":"2017","unstructured":"Hamiditabar M, et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 assessment. Clin Nucl Med. 2017;42:436\u201343.","journal-title":"Clin Nucl Med"},{"key":"1379_CR28","doi-asserted-by":"publisher","first-page":"e23196","DOI":"10.1200\/JCO.2025.43.16_suppl.e23196","volume":"43","author":"S Peters","year":"2025","unstructured":"Peters S, et al. Investigating a biopsychosocial model of fatigue in patients with neuroendocrine neoplasms. J Clin Oncol. 2025;43:e23196\u201323196. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e23196.","journal-title":"J Clin Oncol"},{"key":"1379_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44170","volume":"5","author":"S Das","year":"2022","unstructured":"Das S, et al. External validation of a clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy. JAMA Netw Open. 2022;5:e2144170.","journal-title":"JAMA Netw Open"},{"key":"1379_CR30","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.24.00541","volume":"42","author":"JE Bower","year":"2024","unstructured":"Bower JE, et al. Management of fatigue in adult survivors of cancer: ASCO\u2013Society for Integrative Oncology guideline update. J Clin Oncol. 2024;42:2456\u201387.","journal-title":"J Clin Oncol"},{"key":"1379_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13464","volume":"37","author":"RV Parghane","year":"2025","unstructured":"Parghane RV, Basu S. Toxicity manifestations encountered in peptide receptor radionuclide therapy setting. J Neuroendocrinol. 2025;37:e13464.","journal-title":"J Neuroendocrinol"},{"key":"1379_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01185-4","volume":"14","author":"F Liu","year":"2024","unstructured":"Liu F, et al. Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China. EJNMMI Res. 2024;14:119.","journal-title":"EJNMMI Res"},{"key":"1379_CR33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR34","doi-asserted-by":"publisher","first-page":"990","DOI":"10.2967\/jnumed.124.268522","volume":"66","author":"A Mench","year":"2025","unstructured":"Mench A, et al. Navigating radiation safety after radiopharmaceutical therapies: proposed workflow and essential guidelines for nonspecialists. J Nucl Med. 2025;66:990\u20134. https:\/\/doi.org\/10.2967\/jnumed.124.268522.","journal-title":"J Nucl Med"},{"key":"1379_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/tomography8010029","volume":"8","author":"C Sakulpisuti","year":"2022","unstructured":"Sakulpisuti C, Chamroonrat W, Tepmongkol S. Cutaneous management after extravasation of high-concentrated amino acid solution administered for renal protection in PRRT. Tomography. 2022;8:356\u201363.","journal-title":"Tomography"},{"key":"1379_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","volume":"49","author":"W Makis","year":"2015","unstructured":"Makis W, McCann K, McEwan AJ. The challenges of treating paraganglioma patients with (177)Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols. Nucl Med Mol Imaging. 2015;49:223\u201330. https:\/\/doi.org\/10.1007\/s13139-015-0332-6.","journal-title":"Nucl Med Mol Imaging"},{"key":"1379_CR37","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s00259-011-1826-9","volume":"38","author":"G Giovacchini","year":"2011","unstructured":"Giovacchini G, Nicolas G, Freidank H, Mindt TL, Forrer F. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging. 2011;38:1675\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, et al. Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43:453\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01077-7","volume":"14","author":"M Persson","year":"2024","unstructured":"Persson M, Hindorf C, Ardenfors O, Larsson M, Nilsson JN. Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy. EJNMMI Res. 2024;14:13.","journal-title":"EJNMMI Res"},{"key":"1379_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2967\/jnumed.112.107524","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33\u201341.","journal-title":"J Nucl Med"},{"key":"1379_CR41","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.118.225235","volume":"60","author":"L Hagmarker","year":"2019","unstructured":"Hagmarker L, et al. Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60:1406\u201313.","journal-title":"J Nucl Med"},{"key":"1379_CR42","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/jco.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, et al. Radiolabeled Somatostatin Analog [<\u2009sup\u2009>\u2009177<\/sup\u2009>\u2009Lu-DOTA\u2009<\u2009sup\u2009>\u20090,Tyr\u2009<\u2009sup\u2009>\u20093]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. J Clin Nutr. 2005;23:2754\u201362. https:\/\/doi.org\/10.1200\/jco.2005.08.066.","journal-title":"J. Clin. Nutr."},{"key":"1379_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JGO.2019.5.suppl.81","volume":"5","author":"J Singh","year":"2019","unstructured":"Singh J, Singh GJ. Development of hematologic toxicity with sequential treatment of Y90 followed by PRRT in five patients at single institution with metastatic neuroendocrine patients. J Global Oncol. 2019;5:81\u201381. https:\/\/doi.org\/10.1200\/JGO.2019.5.suppl.81.","journal-title":"J Global Oncol"},{"key":"1379_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00938-1","volume":"9","author":"A Karimi","year":"2025","unstructured":"Karimi A, Bogdani C, O\u2019Dwyer E, Siolas D. Emerging innovations in theranostics for pancreatic neuroendocrine tumors. NPJ Precis Oncol. 2025;9:146. https:\/\/doi.org\/10.1038\/s41698-025-00938-1.","journal-title":"NPJ Precis Oncol"},{"key":"1379_CR45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.hoc.2007.04.009","volume":"21","author":"DJ Kwekkeboom","year":"2007","unstructured":"Kwekkeboom DJ, Teunissen JJ, Kam BL, Valkema R, de Herr WW, Krenning EP. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am. 2007;21:561\u201373.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1379_CR46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/RLU.0000000000000935","volume":"40","author":"BP Riff","year":"2015","unstructured":"Riff BP, et al. Peptide receptor radionuclide therapy\u2013induced hepatotoxicity in patients with metastatic neuroendocrine tumors. Clin Nucl Med. 2015;40:845\u201350.","journal-title":"Clin Nucl Med"},{"key":"1379_CR47","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/MPA.0000000000000919","volume":"46","author":"BW Katona","year":"2017","unstructured":"Katona BW, et al. Efficacy of peptide receptor radionuclide therapy in a united States\u2013based cohort of metastatic neuroendocrine tumor patients: single-institution retrospective analysis. Pancreas. 2017;46:1121\u20136.","journal-title":"Pancreas"},{"key":"1379_CR48","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1634\/theoncologist.2019-0743","volume":"25","author":"JM Heckert","year":"2020","unstructured":"Heckert JM, et al. Abnormal pretreatment liver function tests are associated with discontinuation of peptide receptor radionuclide therapy in a US-based neuroendocrine tumor cohort. Oncologist. 2020;25:572\u20138.","journal-title":"Oncologist"},{"key":"1379_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/oncolo\/oyab072","volume":"27","author":"H Duan","year":"2022","unstructured":"Duan H, et al. Evaluation of liver and renal toxicity in peptide receptor radionuclide therapy for somatostatin receptor expressing tumors: a 2-year follow-up. Oncologist. 2022;27:447\u201352. https:\/\/doi.org\/10.1093\/oncolo\/oyab072.","journal-title":"Oncologist"},{"key":"1379_CR50","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(12)70334-0","volume":"13","author":"ML Smits","year":"2012","unstructured":"Smits ML, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025\u201334.","journal-title":"Lancet Oncol"},{"key":"1379_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235792","volume":"14","author":"MN Becx","year":"2022","unstructured":"Becx MN, Minczeles NS, Brabander T, de Herr WW, Nonnekens J, Hofland J. A clinical guide to peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients. Cancers. 2022;14:5792.","journal-title":"Cancers"},{"key":"1379_CR52","unstructured":"Dailymed. LUTATHERA- lutetium lu 177 dotatate injection, https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55 (."},{"key":"1379_CR53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00259-020-05004-5","volume":"48","author":"RV Parghane","year":"2021","unstructured":"Parghane RV, et al. Long-term outcome of \u201cSandwich\u201d chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging. 2021;48:913\u201323. https:\/\/doi.org\/10.1007\/s00259-020-05004-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR54","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1530\/erc-17-0380","volume":"25","author":"A Bla\u017eevi\u0107","year":"2018","unstructured":"Bla\u017eevi\u0107 A, Hofland J, Hofland LJ, Feelders RA, de Herr WW. Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocr Relat Cancer. 2018;25:R115\u2013r130. https:\/\/doi.org\/10.1530\/erc-17-0380.","journal-title":"Endocr Relat Cancer"},{"key":"1379_CR55","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrendo.2009.51","volume":"5","author":"M Druce","year":"2009","unstructured":"Druce M, Rockall A, Grossman AB. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol. 2009;5:276\u201383. https:\/\/doi.org\/10.1038\/nrendo.2009.51.","journal-title":"Nat Rev Endocrinol"},{"key":"1379_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.242875","volume":"62","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, et al. Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy. J Nucl Med. 2021;62:69\u201372.","journal-title":"J Nucl Med"},{"key":"1379_CR57","doi-asserted-by":"crossref","unstructured":"Wee CE et al. Bowel obstruction as a complication of peptide receptor radionuclide therapy (PRRT). J Nucl Med (2021).","DOI":"10.2967\/jnumed.121.262048"},{"key":"1379_CR58","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262340","volume":"62","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Al-Toubah T, El-Haddad G. Reply: bowel obstruction as a complication of peptide receptor radionuclide therapy. J Nucl Med. 2021;62:1321. https:\/\/doi.org\/10.2967\/jnumed.121.262340.","journal-title":"J Nucl Med"},{"key":"1379_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298824","volume":"19","author":"V Sukrithan","year":"2024","unstructured":"Sukrithan V, et al. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: a single center experience. PLoS One. 2024;19:e0298824. https:\/\/doi.org\/10.1371\/journal.pone.0298824.","journal-title":"PLoS One"},{"key":"1379_CR60","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.108.C33","author":"A Cass","year":"2025","unstructured":"Cass A, Skotte E, Wheless M, Stockton S, Ramirez R. Corticosteroid prophylaxis did not decrease tumor flare reaction in high-risk neuroendocrine tumors patients treated with 177Lu-DOTATATE. Endocr Abstr. 2025. https:\/\/doi.org\/10.1530\/endoabs.108.C33.","journal-title":"Endocr Abstr"},{"key":"1379_CR61","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00259-007-0688-7","volume":"35","author":"M van Essen","year":"2008","unstructured":"van Essen M, Krenning EP, Kam BL, de Herr WW, van Aken MO, Kwekkeboom DJ. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:743\u20138. https:\/\/doi.org\/10.1007\/s00259-007-0688-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11143983","volume":"11","author":"V Zamponi","year":"2022","unstructured":"Zamponi V, et al. Effect of neuroendocrine neoplasm treatment on human reproductive health and sexual function. J Clin Med. 2022;11:3983.","journal-title":"J Clin Med"},{"key":"1379_CR63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4103\/ijnm.IJNM_83_18","volume":"33","author":"S Arora","year":"2018","unstructured":"Arora S, et al. Clinical issues related to fluid management during (177)Lu-Peptide receptor radionuclide therapy in metastatic neuroendocrine tumors with carcinoid heart disease. Indian J Nucl Med. 2018;33:359\u201361. https:\/\/doi.org\/10.4103\/ijnm.IJNM_83_18.","journal-title":"Indian J Nucl Med"},{"key":"1379_CR64","doi-asserted-by":"crossref","unstructured":"Kusne Y, Patnaik MM, Halfdanarson TR, Sonbol MB. Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk? Endocrine-related Cancer 32 (2025).","DOI":"10.1530\/ERC-25-0025"},{"key":"1379_CR65","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/erc-21-0082","volume":"28","author":"M Kesavan","year":"2021","unstructured":"Kesavan M, Grover P, Lam WS, Claringbold PG, Turner JH. Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET. Endocr Relat Cancer. 2021;28:521\u20137. https:\/\/doi.org\/10.1530\/erc-21-0082.","journal-title":"Endocr Relat Cancer"},{"key":"1379_CR66","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/cncr.34191","volume":"128","author":"KR Kennedy","year":"2022","unstructured":"Kennedy KR, Turner JH, MacDonald WBG, Claringbold PG, Boardman G, Ransom DT. Long-term survival and toxicity in patients with neuroendocrine tumors treated with (177) Lu-octreotate peptide radionuclide therapy. Cancer. 2022;128:2182\u201392. https:\/\/doi.org\/10.1002\/cncr.34191.","journal-title":"Cancer"},{"key":"1379_CR67","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2967\/jnumed.124.268640","volume":"66","author":"M Eifer","year":"2025","unstructured":"Eifer M, et al. Therapy-Related myeloid neoplasms after [<\u2009sup\u2009>\u2009177\u2009Lu]Lu-PSMA therapy in patients with metastatic Castration-Resistant prostate cancer: A case series. J Nucl Med. 2025;66:579\u201384. https:\/\/doi.org\/10.2967\/jnumed.124.268640.","journal-title":"J Nucl Med"},{"key":"1379_CR68","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/ERC-21-0082","volume":"28","author":"M Kesavan","year":"2021","unstructured":"Kesavan M, Grover P, Lam W-s, Claringbold PG, Turner JH. Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET. Endocr Relat Cancer. 2021;28:521\u20137.","journal-title":"Endocr Relat Cancer"},{"key":"1379_CR69","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020;6:1086\u201392.","journal-title":"JAMA Oncol"},{"key":"1379_CR70","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"J Hsu","year":"2018","unstructured":"Hsu J, Dayaram T, Tovy A. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018;23:700\u2013713.e706.","journal-title":"Cell Stem Cell"},{"key":"1379_CR71","doi-asserted-by":"publisher","first-page":"e2400221","DOI":"10.1200\/PO.24.00221","volume":"8","author":"A De Jesus-Acosta","year":"2024","unstructured":"De Jesus-Acosta A, Mohindroo C. Genomic landscape of pancreatic neuroendocrine tumors and implications for clinical practice. JCO Precision Oncol. 2024;8:e2400221.","journal-title":"JCO Precision Oncol"},{"key":"1379_CR72","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1158\/1940-6207.CAPR-23-0483","volume":"17","author":"C Mohindroo","year":"2024","unstructured":"Mohindroo C, et al. Germline testing identifies pathogenic\/likely pathogenic variants in patients with pancreatic neuroendocrine tumors. Cancer Prev Res. 2024;17:335\u201342.","journal-title":"Cancer Prev Res"},{"key":"1379_CR73","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","volume":"49","author":"E Schulz","year":"2012","unstructured":"Schulz E, Valentin A, Ulz P. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Genet. 2012;49:422\u20138.","journal-title":"J Med Genet"},{"key":"1379_CR74","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","volume":"115","author":"MR Litzow","year":"2010","unstructured":"Litzow MR, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115:1850\u20137. https:\/\/doi.org\/10.1182\/blood-2009-10-249128.","journal-title":"Blood"},{"key":"1379_CR75","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","volume":"46","author":"I Goncalves","year":"2019","unstructured":"Goncalves I, et al. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Eur J Nucl Med Mol Imaging. 2019;46:1902\u201310. https:\/\/doi.org\/10.1007\/s00259-019-04389-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR76","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1055\/s-0043-1764308","volume":"22","author":"P Chandra","year":"2023","unstructured":"Chandra P, Kumar K. Screening for clonal hematopoiesis for mitigating the risk of hematopoietic neoplasms after PRRT. World J Nucl Med. 2023;22:150\u20131.","journal-title":"World J Nucl Med"},{"key":"1379_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107434","author":"S Pritzl","year":"2024","unstructured":"Pritzl S, Kusne Y, Halfdanarson T. Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to lutetium-177-Dotatate. Leuk Res. 2024. https:\/\/doi.org\/10.1016\/j.leukres.2023.107434.","journal-title":"Leuk Res"},{"key":"1379_CR78","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00259-017-3652-1","volume":"44","author":"A Yordanova","year":"2017","unstructured":"Yordanova A, et al. Safety of multiple repeated cycles of (177)Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017;44:1207\u201314. https:\/\/doi.org\/10.1007\/s00259-017-3652-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR79","unstructured":"Christensen EI, Nielsen S. in Seminars in nephrology. 414\u2013439 (Elsevier)."},{"key":"1379_CR80","first-page":"1388","volume":"37","author":"M de Jong","year":"1996","unstructured":"de Jong M, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388\u201392.","journal-title":"J Nucl Med"},{"key":"1379_CR81","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00259-007-0457-7","volume":"34","author":"EJ Rolleman","year":"2007","unstructured":"Rolleman EJ, Kooij PP, de Herr WW, Valkema R, Krenning EP, de Jong M. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging. 2007;34:1854\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR82","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","volume":"44","author":"M Del Prete","year":"2017","unstructured":"Del Prete M, Buteau F-A, Beauregard J-M. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1379_CR83","doi-asserted-by":"publisher","first-page":"451","DOI":"10.7150\/thno.92487","volume":"14","author":"RP Baum","year":"2024","unstructured":"Baum RP, et al. Long-term nephrotoxicity after PRRT: myth or reality. Theranostics. 2024;14:451\u20139. https:\/\/doi.org\/10.7150\/thno.92487.","journal-title":"Theranostics"},{"key":"1379_CR84","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2967\/jnmt.115.168146","volume":"44","author":"R Ranade","year":"2016","unstructured":"Ranade R, Basu S. 177Lu-DOTATATE PRRT in patients with metastatic neuroendocrine tumor and a single functioning kidney: tolerability and effect on renal function. J Nucl Med Technol. 2016;44:65\u20139.","journal-title":"J Nucl Med Technol"},{"key":"1379_CR85","volume":"1","author":"E Kalogianni","year":"2015","unstructured":"Kalogianni E, Ruiz DL, Corcoran BJ, Devlin LA, Vivian GC, Mulholland NJ. 177Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis\u2014dosimetric considerations. BJR| case reports. 2015;1:20150177.","journal-title":"BJR| case reports"},{"key":"1379_CR86","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2967\/jnumed.123.266619","volume":"65","author":"A Moraitis","year":"2024","unstructured":"Moraitis A, et al. Safety and efficacy of <\u2009em\u2009>\u2009Para-Aminohippurate coinfusion for renal protection during peptide receptor radiotherapy in patients with neuroendocrine tumors. J Nucl Med. 2024;65:931\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.266619.","journal-title":"J Nucl Med"},{"key":"1379_CR87","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1148\/radiol.2020201745","volume":"298","author":"BJ Burkett","year":"2021","unstructured":"Burkett BJ, et al. How we do it: a multidisciplinary approach to (177)Lu DOTATATE peptide receptor radionuclide therapy. Radiology. 2021;298:261\u201374. https:\/\/doi.org\/10.1148\/radiol.2020201745.","journal-title":"Radiology"},{"key":"1379_CR88","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/mpa.0000000000002002","volume":"51","author":"AE Hendifar","year":"2022","unstructured":"Hendifar AE, Mehr SH, McHaffie DR. Best practices for the coordinated care of patients with neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Pancreas. 2022;51:213\u20138. https:\/\/doi.org\/10.1097\/mpa.0000000000002002.","journal-title":"Pancreas"},{"key":"1379_CR89","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.hoc.2022.07.005","volume":"36","author":"C Mohindroo","year":"2022","unstructured":"Mohindroo C, McAllister F, De Jesus-Acosta A. Genetics of pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am. 2022;36:1033\u201351. https:\/\/doi.org\/10.1016\/j.hoc.2022.07.005.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1379_CR90","doi-asserted-by":"publisher","first-page":"e212274","DOI":"10.1001\/jamanetworkopen.2021.2274","volume":"4","author":"ST Kipnis","year":"2021","unstructured":"Kipnis ST, et al. Laboratory, Clinical, and survival outcomes associated with peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. JAMA Netw Open. 2021;4:e212274. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.2274.","journal-title":"JAMA Netw Open"},{"key":"1379_CR91","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/jco.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41:5049\u201367. https:\/\/doi.org\/10.1200\/jco.23.01529.","journal-title":"J Clin Oncol"},{"key":"1379_CR92","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172\u201385.","journal-title":"Neuroendocrinology"},{"key":"1379_CR93","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2478\/raon-2019-0040","volume":"53","author":"V Granata","year":"2019","unstructured":"Granata V, et al. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist\u2019s challenge. Radiol Oncol. 2019;53:373\u201387. https:\/\/doi.org\/10.2478\/raon-2019-0040.","journal-title":"Radiol Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01379-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:33:23Z","timestamp":1781631203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01379-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01379-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RR reports consulting roles with ITM Radiopharma, TerSera Therapeutics, Exelixis, Novartis, Lantheus, and Sanofi, and participation in the Speakers Bureau for AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}